NewsDialy

Palvella Therapeutics files first NDA module for rare lymphatic disease drug, holds $250.6 million in cash

8/4/2026

A drug application that lets the FDA begin reviewing completed portions before the full package arrives has reached federal regulators for a treatment targeting a serious, rare condition with no approved therapies in the United States.

Palvella Therapeutics (Nasdaq: PVLA) submitted the first module of that rolling New Drug Application, a phased filing process the FDA grants to allow parallel review of completed sections, for QTORIN rapamycin in microcystic lymphatic malformations.

The Wayne, Pennsylvania company reported $250.6 million in cash, cash equivalents, and short-term investments as of June 30, 2026.

NDA submission and the path to a 2027 launch Palvella completed an in-person pre-NDA meeting with the FDA before initiating the rolling submission, covering nonclinical, clinical pharmacology, clinical information, and the planned evidence package.